Medical tech company Masimo (NASDAQ:MASI) will be reporting earnings tomorrow after the bell. Here’s what to look for.

Bernstein raised the firm’s price target on Insulet (PODD) to $335 from $315 following a strong quarter and an “impressive” outside-U.S.

Principal Financial Group Inc. trimmed its stake in Insulet Co. (NASDAQ:PODD – Free Report) by 0.3% during the fourth quarter ...

Insulet (NASDAQ:PODD – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Raymond ...

Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more ...

Shares of Insulet Corp. PODD slid 1.90% to $282.80 Friday, on what proved to be an all-around dismal trading session for the ...

Insulet's Q4 sales grew 17.2% to $597.5 million, exceeding forecasts. Omnipod revenue surged, and 2025 guidance projects up to 20% growth.

Raymond James analyst Jayson Bedford raised the firm’s price target on Insulet (PODD) to $328 from $294 and keeps an Outperform rating on the ...

Insulet (PODD) delivered earnings and revenue surprises of 9.52% and 2.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2024 results , with sales up 17.2% year on year to ...

Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps.

Insulet Corp. (PODD) on Thursday reported fourth-quarter profit of $100.7 million. On a per-share basis, the Acton, Massachusetts-based company said it had ...